CONMED Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. CONMED Corporation is a medical technology company providing devices and equipment for surgical procedures, primarily in orthopedic and general surgery. The company operates as a single reporting segment. During the quarter, the company executed a strategic exit from its gastroenterology product lines, selling related assets for $7.0 million and recording a $3.9 million gain.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $317.0 million | $321.3 million |
| Gross Profit | $183.4 million | $177.8 million |
| Gross Margin | 57.9% | 55.3% |
| Operating Income | $25.4 million | $16.0 million |
| Net Income | $13.8 million | $6.0 million |
| Diluted EPS | $0.45 | $0.19 |
| Operating Cash Flow | $13.5 million | $41.5 million |
| Total Debt (Long-term + Current) | $861.6 million | $835.6 million |
| Cash and Equivalents | $35.0 million | $40.8 million |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 1.3% year-over-year, driven by the exit from gastroenterology products (sales dropped from $25.0M to $9.5M). This was partially offset by a 6.8% increase in Orthopedic surgery sales.
- Profitability: Net income more than doubled to $13.8 million. Gross margin expanded 260 basis points to 57.9%, aided by a $1.9 million benefit from terminating a distribution agreement and favorable foreign currency impacts.
- Expenses: Selling and administrative expenses decreased 4.8% due to the absence of $12.2 million in advisory compensation costs incurred in Q1 2025 and a $3.9 million gain on asset sales. However, R&D expenses increased 26% to $16.3 million due to investments in growth drivers and EU regulatory compliance.
- Cash Flow: Operating cash flow declined significantly to $13.5 million from $41.5 million, primarily due to increased inventory builds to mitigate supply chain challenges and higher incentive compensation payments.
- Capital Allocation: The company repurchased $37.0 million of common stock in Q1 2026. Dividend payments were suspended to fund the repurchase program.
Outlook, Risks, and Management Commentary
- Guidance: The filing does not provide specific numerical guidance for the full year 2026. Management expects to repurchase at least $25.0 million in shares annually, with $61.8 million planned for 2026.
- Debt Maturity: The company holds $800.0 million in 2.250% Convertible Notes maturing on June 15, 2027. Management intends to secure incremental financing to fund this maturity but noted there is no assurance of obtaining acceptable terms.
- Risks: Key risks include supply chain constraints, inflationary pressures on manufacturing costs, and potential impacts from tariffs. The company is currently pursuing refund claims for tariffs previously paid under IEEPA following a Supreme Court ruling.
- Personnel: Andrew Moller, Interim Principal Financial Officer, notified the company of his departure effective May 31, 2026. CEO Patrick J. Beyer will serve as interim PFO until a replacement is appointed.
Investor Verification Checklist
- Debt Refinancing: Verify the company's progress in securing financing for the $800 million convertible note maturity in June 2027.
- Dividend Policy: Confirm the status of dividend payments, which are currently suspended in favor of share repurchases.
- Leadership Transition: Monitor the appointment of a permanent Chief Financial Officer following the departure of the Interim PFO.
- Tariff Refunds: Track the status of refund claims for tariffs paid under IEEPA, which could impact future cash flows.
- Inventory Levels: Assess the impact of increased inventory levels on future working capital requirements and cash flow generation.